Abstract
Mammalian target of rapamycin (mTOR), an important sensor for growth factors, nutritional deprivation and other stresses in controling translation, plays a critical role in tumorigenesis. Several rapalogs exhibited antitumor activity clinically, with a modest average response rate, while a small subset of patients exhibited significantly greater clinical benefits. A better understanding of cellular mechanisms and the results of clinical studies can help identify an optimal biomarker to predict the efficacy of mTOR inhibitors. We discuss these potential markers in terms of selection of candidates, baseline expression, pathway inhibition and source of targeted protein.
| Original language | English |
|---|---|
| Pages (from-to) | 4235-4244 |
| Number of pages | 10 |
| Journal | Anticancer Research |
| Volume | 32 |
| Issue number | 10 |
| Publication status | Published - Oct 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biomarker
- Rapamycin
- Review
- mTOR inhibitor
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Markers for efficacy of mammalian target of rapamycin inhibitor'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS